尔康制药：双主业协同发力 上半年净利润同比增长497.36%

Core Viewpoint - Erkang Pharmaceutical reported significant growth in both revenue and net profit for the first half of 2025, indicating successful strategic initiatives and market adaptation [1][2]. Financial Performance - The company achieved operating revenue of 680 million yuan, representing a year-on-year increase of 9.74% [1]. - Net profit reached 37.63 million yuan, showing a substantial year-on-year growth of 497.36% [1]. Business Development - In the pharmaceutical sector, the company is focusing on innovation and international expansion, successfully entering the African market [1]. - A new production project in Tanzania has been initiated, with an investment of 10 million USD aimed at upgrading local facilities to meet international standards for solid dosage forms [1]. Strategic Focus - The company aims to broaden its business reach and create new profit growth points through the Tanzanian project, which is expected to positively impact operational scale and performance [1]. - In the renewable materials sector, the company reported revenue of 127 million yuan, with a significant year-on-year increase, contributing to 18.57% of total revenue [2]. Future Outlook - The company plans to continue focusing on core strategies while enhancing its domestic business and accelerating the development of pharmaceutical and renewable energy operations in Africa [2]. - Efforts will be made to optimize talent structure and operational efficiency to achieve annual business goals [2].